1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering,...
-
Upload
cory-walton -
Category
Documents
-
view
213 -
download
0
Transcript of 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering,...
![Page 1: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/1.jpg)
1
![Page 2: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/2.jpg)
OUR MISSIONTo reduce the burden of malaria in disease-endemic countries
by discovering, developing and facilitating access of new, effective and affordable anti-malaria medicines.
2
60 peopleGeneva-based
300 partnersAfrica 67
Americas 89Asia-Oceania 70
Europe 79
37 projects In pipeline
Research 21Translational 9Phase IIB/III 5
4 products launched>210 million
peopletreated
![Page 3: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/3.jpg)
![Page 4: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/4.jpg)
Syndicated investmentProjected funding: 1999 to 2017
4
![Page 5: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/5.jpg)
Leveraging donor funds
MMV
£1.00
+
Pharma ‘in-kind’
£1.50 =
total
£3.50
Pharma ‘co-funding’
£1.00
![Page 6: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/6.jpg)
TCP1 TCP2 TCP3a TCP3b TCP4
A Liver-stage schizontsB Blood-stage schizontsC GametocytesD Micro- and Macro-gametes/zygotesE OokinetesF OocystsG Sporozoites
P. cynomolgi hypnozoite assay BPRC, Netherlands
P. yoelii/berghei liver stage assayGNF Novartis/ UCSD, USA
In vitro blood stage activitySwiss TPH, Switzerland & Eskitis, Australia
Parasite Reduction Rate in vivo hu-SCID modelGSK Tres Cantos, Spain
Resistance risk assessmentColumbia University, USA
Gametocycte and gamete formation assaysGriffith University Australia and Imperial College UK
Gametocycte assayGSK Tres Cantos, Spain
Membrane feed assayImperial College, UK
Membrane feed assayTropIQ, NetherlandsGSK, Tres Cantos
MMV has assembled a network of partners/assays to select molecules with required properties
Network of partners/assays
Industry ●Academia ●
![Page 7: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/7.jpg)
MMV–partnership pipeline Q1 2014
![Page 8: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/8.jpg)
Focusing resourcesthrough early project prioritisation
4 2 41534
4 3 2942
Before GLPpreclinical
GLP preclinical Phase I Phase II Phase III Launched
Active
Terminated
![Page 9: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/9.jpg)
Reducing costsin clinical development
INDUSTRY$180 MILLION
Industry estimates for clinicaldevelopment of an anti-infective
(Tufts)
MMV$54 MILLION*
Total clinical development costsfor pyronaridine-artesunate
* Includes direct internal project costs, CRO costs and MMV management & administration costs.
70%REDUCTION
![Page 10: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/10.jpg)
INITIALCOST
PROPOSAL
Reducing partner & vendor costse.g. non-clinical toxicology study
![Page 11: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/11.jpg)
INITIALCOST
PROPOSAL
CRO BID
Reducing partner & vendor costse.g. non-clinical toxicology study
73%REDUCTION
![Page 12: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/12.jpg)
INITIALCOST
PROPOSAL
CRO BID
MMV SHARE
Reducing partner & vendor costse.g. non-clinical toxicology study
50%OF CRO BID
13%OF INITIALPROPOSAL
![Page 13: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/13.jpg)
Access and affordability
ACT47%REDUCTION
Terms of MMV alliance agreements
+ Obligation to launch inmalaria-endemic countries
+ Price targets & cost audits
![Page 14: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/14.jpg)
UK 23 pence* to treat one child
* cost for one 3-day course of Coartem-dispersible (Novartis public sector price for malaria-endemiccountries; weighted average treatment regimen 2012; March 1st 2013 exchange rate)
![Page 15: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/15.jpg)
>212 million treatmentsdelivered and counting
![Page 16: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/16.jpg)
Coartem Dispersible
60-87 million children cured200 million treatment courses delivered
* estimates based upon drug distribution data, epidemiology / testing data and clinical efficacy data(PCR-corrected 28-day cure rate for Coartem Dispersible)
![Page 17: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/17.jpg)
Impact beyond malaria
![Page 18: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/18.jpg)
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
![Page 19: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/19.jpg)
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
3 chemical series
![Page 20: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/20.jpg)
Providing researchers with
400 anti-malaria compoundsto further R&D in other NTDs
2 tropical diseasesSleeping sicknessLeishmaniasis
![Page 21: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/21.jpg)
MMV is grateful for the financial support from the following organizations:
21
![Page 22: 1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.](https://reader035.fdocuments.net/reader035/viewer/2022081603/56649d9e5503460f94a88183/html5/thumbnails/22.jpg)